Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation.

Nature structural biology | Nov 19, 1998

http://www.ncbi.nlm.nih.gov/pubmed/9808045

Dimerization of the erythropoietin (EPO) receptor (EPOR), in the presence of either natural (EPO) or synthetic (EPO-mimetic peptides, EMPs) ligands is the principal extracellular event that leads to receptor activation. The crystal structure of the extracellular domain of EPOR bound to an inactive (antagonist) peptide at 2.7 A resolution has unexpectedly revealed that dimerization still occurs, but the orientation between receptor molecules is altered relative to active (agonist) peptide complexes. Comparison of the biological properties of agonist and antagonist EMPs with EPO suggests that the extracellular domain orientation is tightly coupled to the cytoplasmic signaling events and, hence, provides valuable new insights into the design of synthetic ligands for EPOR and other cytokine receptors.

Pubmed ID: 9808045 RIS Download

Mesh terms: Amino Acid Sequence | Animals | Conserved Sequence | Crystallography, X-Ray | DNA-Binding Proteins | Dimerization | Erythropoietin | Humans | Mice | Milk Proteins | Models, Molecular | Molecular Sequence Data | Peptides, Cyclic | Phosphorylation | Protein Conformation | Receptors, Erythropoietin | Recombinant Fusion Proteins | STAT5 Transcription Factor | Signal Transduction | Trans-Activators | Tryptophan | Tyrosine

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

None

Mouse Genome Informatics (Data, Gene Annotation)

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.